Levin Capital Strategies, L.P. Gamida Cell Ltd. Transaction History

Levin Capital Strategies, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 16, 2024	SELL	$0.04 - $0.46 $91,039 - $1.05 Million	-2,275,999 Reduced 37.78%	3,747,630 $149,000
Q4 2023 Feb 06, 2024	BUY	$0.25 - $1.02 $832,588 - $3.4 Million	3,330,355 Added 123.65%	6,023,629 $2.47 Million
Q3 2023 Oct 31, 2023	BUY	$0.85 - $1.87 $33,150 - $72,930	39,000 Added 1.47%	2,693,274 $2.77 Million
Q2 2023 Jul 31, 2023	SELL	$0.73 - $2.37 $32,969 - $107,038	-45,164 Reduced 1.67%	2,654,274 $5.12 Million
Q1 2023 Apr 24, 2023	BUY	$0.68 - $1.71 $1.51 Million - $3.81 Million	2,227,882 Added 472.45%	2,699,438 $2.19 Million
Q4 2022 Feb 13, 2023	BUY	$1.15 - $2.1 $513,539 - $937,767	446,556 Added 1786.22%	471,556 $608,000
Q3 2022 Nov 08, 2022	BUY	$1.53 - $3.39 $38,250 - $84,750	25,000 New	25,000 $40,000
Q2 2022 Aug 15, 2022	SELL	$1.73 - $4.29 $34,600 - $85,800	-20,000 Closed	0 $0
Q1 2022 May 02, 2022	SELL	$2.22 - $4.47 $111,000 - $223,500	-50,000 Reduced 71.43%	20,000 $83,000
Q4 2021 Feb 15, 2022	BUY	$2.2 - $4.46 $154,000 - $312,200	70,000 New	70,000 $178,000

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Levin Capital Strategies, L.P., based on Form 13F filings with the SEC.

Stay updated on Levin Capital Strategies, L.P. with notifications on news.